GGrantIndex
Sort

21,281 grants matching influenza

Self-administered microneedle patches for influenza vaccines

$1,410,179
Richard W Compans · Emory University · U01 · FY2008 · AI

Portable Multiplexed LATE-PCR Influenza Test

$1,409,513
Barry E Boyes · Smiths Detection, Inc. · U01 · FY2009 · AI

Development of drugs that target the M2 proton channel from the influenza A Virus

$1,408,915
William F Degrado · University Of California, San Francisco · U01 · FY2012 · AI

Immunobiology and Virology of Influenza A Virus

$1,408,875
Jonathan W Yewdell · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Pandemic Influenza Translational Research and novel universal countermeasure development

$1,406,345
Matthew Memoli · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Clinical and Biostatistics Core

$1,405,948
Wilbur H. Chen · Univ Of Maryland, College Park · U19 · FY2022 · AI

CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)

$1,405,016
Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · N01 · FY2018 · AI

High-Throughput Molecular Profiling Core

$1,403,983
Michael G Katze · Univ Of North Carolina Chapel Hill · U19 · FY2012 · AI

T Cell Memory to Pathogens: Generation and Function

$1,403,973
Susan L Swain · Trudeau Institute, Inc. · P01 · FY2009 · AI

Comprehensive multimodal analysis of patients with neuroimmunological diseases

$1,402,526
Bibiana Bielekova · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI

Influenza Vaccine Development

$1,402,202
Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI

Influenza Vaccine Development

$1,402,202
Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI

Influenza Vaccine Development

$1,402,202
Barney Graham · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI

IP21-002, New Vaccine Surveillance Network

$1,402,123
John V Williams · University Of Pittsburgh At Pittsburgh · U01 · FY2021 · IP

Facility Management, Maintenance and Operations Core

$1,401,116
Sixto Manuel Leal · University Of Alabama At Birmingham · UC7 · FY2023 · AI

Emerging respiratory viruses - pathogenesis and countermeasures

$1,400,690
Emmie De Wit · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

Section on High Resolution Optical Imaging

$1,400,493
Hari Shroff · National Institute Of Biomedical Imaging And Bioengineering · ZIA · FY2014 · EB

RFA-IP-22-004, Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines

$1,400,000
Emily Toth Martin · University Of Michigan At Ann Arbor · U01 · FY2023 · IP

RFA-IP-22-004, Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027

$1,400,000
Karen J Wernli · Kaiser Foundation Health Plan Of Washington · U01 · FY2023 · IP

RFA-IP-22-004, Evaluating influenza, SARS-CoV-2, and other respiratory virus vaccine effectiveness in prevention of acute illness in Washington state 2022-2027

$1,400,000
Karen J Wernli · Kaiser Foundation Health Plan Of Washington · U01 · FY2024 · IP

RFA-IP-22-004:Michigan-Ford Initiative to Measure Vaccine Effectiveness (MFIVE): Seasonal Influenza, COVID-19 and Respiratory Virus Vaccines

$1,400,000
Emily Toth Martin · University Of Michigan At Ann Arbor · U01 · FY2024 · IP

DNA Based Generation of Avian Influenza virus Vaccines

$1,400,000
Sanofi Pasteur, Inc. · UC1 · FY2000 · AI

RFA-IP-22-004, Component A _ Credible Effectiveness Measures of Seasonal Influenza, COVID-19 and Other Respiratory Virus Vaccines against Ambulatory Care for Acute Illness in Texas (and Component D).

$1,400,000
Manjusha Gaglani · Baylor Research Institute · U01 · FY2024 · IP

Strengthening Influenza Surveillance (WHO/EMRO)

$1,400,000
Hassan El-Mahdi El-Bushra · World Hlth Org- -E Mediterranean Office · U51 · FY2008 · CI

RFA-IP-22-004, Component A _ Credible Effectiveness Measures of Seasonal Influenza, COVID-19 and Other Respiratory Virus Vaccines against Ambulatory Care for Acute Illness in Texas (and Component D).

$1,400,000
Manjusha Gaglani · Baylor Research Institute · U01 · FY2023 · IP